New Drugs 2016
Originally presented at HOPA's 13th Annual Conference, March 2017.
This session will provide an overview of all hematology/oncology drugs newly approved by FDA in 2016, plus expanded indications of existing drugs. Attendees will be able to identify appropriate use, key toxicities, and appropriate management of such toxicities.
- Describe the mechanisms of action of hematology/oncology drugs approved by the U.S. Food and Drug Administration (FDA) in 2016.
- Summarize key data supporting approval and the purported clinical benefits of these drugs.
- Identify common adverse events and appropriate prevention or management of such events.
Vivian Park, PharmD MBA BCOP
Vivian Park received her PharmD from the University of Southern California School of Pharmacy and her MBA from New York University Stern School of Business. She currently manages drug policy, pharmacy and therapeutics, along with pharmacy training and education, and serves as the Accreditation Council for Pharmacy Education administrator at Memorial Sloan Kettering Cancer Center. She completed her oncology residency at the University of Maryland School of Pharmacy and was a clinical specialist in adult bone marrow transplant and also in pediatric oncology. She served on the HOPA Board of Directors as treasurer from 2010 to 2012.
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .1 CEU
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020